Wang et al. (2008) demonstrated that SDF-1/CXCR7 promoted Akt phosphorylation in prostate cancer. CXCR7 could also increase the p-Akt level in osteosarcoma (Zhang et al., 2014), bladder cancer (Hao et al., 2012), thyroid cancer (Zhu et al., 2016), and multiple myeloma (Azab et al., 2014). The gene discussed is ACKR3; the disease is prostate carcinoma.